WHAT IS CLAIMED:

1. Use of a serotonin agonist in the manufacture of a medicament~~A method~~ for preventing or treating a psychological disorder, wherein~~comprising~~ the medicament is to be ~~step of:~~

~~——~~administered~~ing a serotonin agonist~~ in combination with a serotonin receptor 2A antagonist, and wherein the medicament~~said agonist~~ is to be administered separately, sequentially or simultaneously with the serotonin receptor 2A~~said~~ antagonist.

2. The use~~method~~ of claim 1, wherein the~~said~~ serotonin agonist is psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine~~.~~, carboxamindotryptamine, ibogaine, 3,4-methylenedioxy-methamphetamine (MDMA), or a derivative~~compound that promotes a release of serotonin~~ or metabolite~~a combination~~ thereof.

3. The use~~method~~ of claim 2, wherein the~~said~~ serotonin agonist is psilocybin or psilocin or a derivative thereof.

4. The use~~method~~ of claim 3, wherein said derivative of psilocybin or psilocin is [3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate or 4-hydroxy-N,N,N-trimethyltryptamine.

5. The use~~method~~ of claim 3, wherein the psilocybin or psilocin is present in the form of an extract from a mushroom and/or truffle (sclerotium).

6. The use~~method~~ of claim 5, wherein the~~said~~ mushroom or truffle is from the genus *Psilocybe*, *Gymnopilus*, *Panaeolus*, *Copelandia*, *Hypholoma*, *Pluteus*, *Inocybe*, *Conocybe*, *Panaeolina*, *Gerronema*, *Agrocybe*, *Galerina* and/or *Mycena*.

7. The usemethod of claim 6, wherein thesaid mushroom or truffle is *P. azurescens*, *P. semilanceata*, *P. cyanescens*, *P. cubensis*, P. *subcubensis*, P. *tampanensis*, P. *mexicana*, P. *atlantis*, and/or P. *semilanceata*.

8. The usemethod of claim 2, wherein the ~~compound that promotes the release of~~ serotonin agonist is 3,4-~~M~~methylenedioxy-methamphetamine (MDMA) or a metabolite thereof.

9. The usemethod of claim 8, wherein the metabolite of MDMA is 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 4-hydroxy-3-methoxyamphetamine (HMA), 3,4-dihydroxyamphetamine (DHA), 3,4-methylenedioxyphenylacetone (MDP2P), or 3,4-methylenedioxy-N-hydroxyamphetamine (MDOH).

10. The usemethod of claim 1, wherein thesaid serotonin receptor 2A antagonist is MDL-11,939, ketanserin, ritanserin, altanserin, acepromazine, mianserin, quetiapine, SB204741, SB206553, SB242084, LY272015, SB243213, Blonanserin, SB200646, RS102221, nefazodone, or MDL-100,907.

11. The usemethod of claim 1, wherein the psychological disorder is depression, psychotic disorder, schizophrenia, schizophreniform disorder (acute schizophrenic episode), schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis), bipolar II disorder, major depressive disorder with psychotic feature (psychotic depression), delusional disorders (paranoia), shared Psychotic Disorder (shared paranoia disorder), Brief Psychotic disorder (other and unspecified Reactive Psychosis), psychotic disorder not otherwise specified (unspecified psychosis), paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, anxiety disorder, panic disorder, panic attacks, agoraphobia, attention deficit syndrome, premenstrual dysphoric disorder, premenstrual syndrome, ADHD, ADD, anorexia nervosa, antisocial personality disorder, autism, addiction, avoidant personality disorder, bipolar disorder, bulimia nervosa, borderline personality disorder, catatone schizophrenia, chronic motor or vocal tic disorder, conversion disorder, cyclothymia, dependent personality disorder, delier,

dementia, depersonalization disorder, depression, Dhat syndrome, dissociative amnesia, dissociative fugue, dissociative identity disorder, dissociative disorder, dissociative disorder, not otherwise specified, dysthymic disorder, Da Costa's syndrome, ephobophilia, exhibitionism, generalized anxiety disorder, grandiose delusions, hypochondria, hoarding disorder, intermittent explosive disorder, jealousy, kleptomania, Kluver-Bucy syndrome, maternity psychosis, mental retardation, monomania, Munchhausen syndrome, misophony, narcissistic personality disorder, obsessive-compulsive disorder, oniomania, organic personality disorder, phobia, paranoid personality disorder, paranoid delusions, passive-aggressive personality, pathological gambling, pathological lying, personality disorder not otherwise defined, pervasive developmental disorder, pica, pain disorder, post encephalitic syndrome, postpartum depression, posttraumatic stress disorder, psychosis, psychotic disorder due to substance use, pyromania, querulant delusions, ruminational disorder, schizophrenia, schizoaffective disorder, schizoid personality disorder, schizotypal personality disorder, separation anxiety, social phobia, somatisation disorder, somatic delusion, somatoform disorder, syndrome of Capgras, syndrome of Cotard, syndrome of Ganser, syndrome of Gilles de la Tourette, selective mutism, theatrical personality disorder, trichotillomania, or undifferentiated somatoform disorder.

12. Use of an agonist of a serotonin receptor in the manufacture of a medicamentA method for preventing or treating a psychological disorder, whereincomprising the medicament is to be step of:

administereding an agonist of serotonin receptors in combination with a serotonin receptor 2A antagonist, and wherein the medicamentsaid agonist is to be administered separately, sequentially or simultaneously with the serotonin receptor 2Asaid antagonist.

13. The usemethod of claim 12, wherein thesaid agonist of serotonin receptors is an agonist of serotonin receptor 1B, serotonin receptor 4, serotonin receptor 6, or serotonin receptor 7.

14. The usemethod of claim 13, wherein thesaid agonist is an agonist of serotonin receptor 1B and is selected from the group consisting of ergotamine,

oxymetazoline, sumatriptan, zolmitriptan, 5-carboxamidotryptamine, CGS-12066A, CP-93,129, CP-94,253, CP-122,288, CP135,807, RU24969, vortioxetine, psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine, and~~or~~ carboxamindotryptamine~~ or combinations thereof~~.

15. The use~~method~~ of claim 13, wherein the~~said~~ agonist is an agonist of serotonin receptor 4 and is selected from the group consisting of BIMU-8, Cisapride, CJ-033, ML-10302, Mosapride, Prucalopride, Renzapride, RS-67506, RS-67333, SL65.0155, Tegaserod, Zacopride, Metoclopramide, Sulpiride, psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine, and~~or~~ carboxamindotryptamine~~ or combinations thereof~~.

16. The use~~method~~ of claim 13, wherein the~~said~~ agonist is an agonist of serotonin receptor 6 and is selected from the group consisting of EMD 386088, E-6801, WAY 181187, and~~or~~ WAY 208466.

17. The use~~method~~ of claim 13, wherein the~~said~~ agonist is an agonist of serotonin receptor 7 and is selected from the group consisting of 5-carboxamidotryptamine, 5-methoxytryptamine, 8-OH-DPAT, aripiprazole, AS-19, E-55888, E-57431, 4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide, 4-[2-(methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide, LP-211, MSD-5a, N-methylserotonin, N-1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, N,N-dimethytryptamine, AGH-107, AH-494, AGH-192, psilocybin, psilocin, baeocystin, norbaeocystin, lisurgide, LSD, dimethyltryptamine, and~~or~~ carboxamindotryptamine~~ or combinations thereof~~.

18. The use~~method~~ of claim 13, wherein the~~said serotonin~~ agonist of the serotonin receptor is ~~a derivative of~~ psilocybin or psilocin or a derivative thereof.

19. The use~~method~~ of claim 18, wherein the~~said~~ derivative of psilocybin or psilocin is [3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-

hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, or 4-hydroxy-N,N,N-trimethyltryptamine.

20. The use~~method~~ of claim 18, wherein the psilocybin or psilocin is present in the form of an extract from a mushroom and/or truffle (sclerotium).

21. The use~~method~~ of claim 17, wherein the~~said~~ mushroom or truffle is from the genus *Psilocybe*, *Gymnopilus*, *Panaeolus*, *Copelandia*, *Hypholoma*, *Pluteus*, *Inocybe*, *Conocybe*, *Panaeolina*, *Gerronema*, *Agrocybe*, *Galerina* and/or *Mycena*.

22. The use~~method~~ of claim 21, wherein the~~said~~ mushroom or truffle is *P. azurescens*, *P. semilanceata*, *P. cyanescens*, *P. cubensis*, P. *subcubensis*, P. *tampanensis*, P. *mexicana*, P. *atlantis*, and/or P. *semilanceata*.

23. The use~~method~~ of claim 12, wherein the~~said~~ serotonin receptor 2A antagonist is MDL-11,939, ketanserin, ritanserin, altanserin, acepromazine, mianserin, quetiapine, SB204741, SB206553, SB242084, LY272015, SB243213, Blonanserin, SB200646, RS102221, nefazodone, or MDL-100,907.

24. The use~~method~~ of claim 12, wherein the psychological disorder is depression, psychotic disorder, schizophrenia, schizophreniform disorder (acute schizophrenic episode), schizoaffective disorder; bipolar I disorder (mania, manic disorder, manic-depressive psychosis), bipolar II disorder, major depressive disorder with psychotic feature (psychotic depression), delusional disorders (paranoia), shared Psychotic Disorder (shared paranoia disorder), Brief Psychotic disorder (other and unspecified Reactive Psychosis), psychotic disorder not otherwise specified (unspecified psychosis), paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, anxiety disorder, panic disorder, panic attacks, agoraphobia, attention deficit syndrome, premenstrual dysphoric disorder, premenstrual syndrome, ADHD, ADD, anorexia nervosa, antisocial personality disorder, autism, addiction, avoidant personality disorder, bipolar disorder, bulimia nervosa, borderline personality disorder, catatone schizophrenia, chronic motor or vocal tic disorder, conversion disorder, cyclothymia, dependent personality disorder, delier,

dementia, depersonalization disorder, depression, Dhat syndrome, dissociative amnesia, dissociative fugue, dissociative identity disorder, dissociative disorder, dissociative disorder, not otherwise specified, dysthymic disorder, Da Costa's syndrome, ephobophilia, exhibitionism, generalized anxiety disorder, grandiose delusions, hypochondria, hoarding disorder, intermittent explosive disorder, jealousy, kleptomania, Kluver-Bucy syndrome, maternity psychosis, mental retardation, monomania, Munchhausen syndrome, misophony, narcissistic personality disorder, obsessive-compulsive disorder, oniomania, organic personality disorder, phobia, paranoid personality disorder, paranoid delusions, passive-aggressive personality, pathological gambling, pathological lying, personality disorder not otherwise defined, pervasive developmental disorder, pica, pain disorder, post encephalitic syndrome, postpartum depression, posttraumatic stress disorder, psychosis, psychotic disorder due to substance use, pyromania, querulant delusions, ruminational disorder, schizophrenia, schizoaffective disorder, schizoid personality disorder, schizotypal personality disorder, separation anxiety, social phobia, somatisation disorder, somatic delusion, somatoform disorder, syndrome of Capgras, syndrome of Cotard, syndrome of Ganser, syndrome of Gilles de la Tourette, selective mutism, theatrical personality disorder, trichotillomania, or undifferentiated somatoform disorder.